{"commentary":{"count":125,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":69,"youtube":33,"x_thread":22,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03505710\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DESTINY-Lung01","nct_id":"NCT03505710","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-lung01-nct03505710. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DESTINY-Lung01","arms":[{"description":"Participants with HER2-overexpressing(immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).","label":"Cohort 1: HER2 Overexpressing","type":"EXPERIMENTAL"},{"description":"Participants with HER2-overexpressing (immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).","label":"Cohort 1a: HER2 Overexpressing","type":"EXPERIMENTAL"},{"description":"Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).","label":"Cohort 2: HER2 Mutated","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Co., Ltd.","AstraZeneca"],"completion_date":{"date":"2024-04-17","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":181,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"}],"last_update":"2025-05-30","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC) (DESTINY-Lung01)","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-05-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)","timeFrame":"From screening, up to 36 months (data cut-off)"}],"references":[{"citation":"Smit EF. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study. Future Oncol. 2024;20(27):1961-1971. doi: 10.1080/14796694.2024.2355724. Epub 2024 Jul 16.","pmid":"39012221","type":"DERIVED"},{"citation":"Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodriguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Janne PA. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.","pmid":"38547891","type":"DERIVED"},{"citation":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.","pmid":"34534430","type":"DERIVED"}],"start_date":{"date":"2018-05-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03505710"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-lung01-nct03505710"}